MARKET

ARVN

ARVN

Arvinas
NASDAQ
7.31
+0.01
+0.14%
Opening 15:42 10/26 EDT
OPEN
7.32
PREV CLOSE
7.30
HIGH
7.41
LOW
7.23
VOLUME
289.62K
TURNOVER
--
52 WEEK HIGH
14.51
52 WEEK LOW
6.74
MARKET CAP
477.97M
P/E (TTM)
45.57
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARVN last week (1012-1016)?
Weekly Report · 10/19 09:17
Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs
The Wall Street Journal · 10/15 09:30
Weekly Report: what happened at ARVN last week (1005-1009)?
Weekly Report · 10/12 09:18
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN) and Ovid Therapeutics (OVID)
TipRanks · 10/08 12:40
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO)
TipRanks · 10/08 09:20
Arvinas Fell While It Turned A Profit
Simply Wall St · 10/08 07:30
Arvinas' ARV-102 Shows Biomarker Changes In Parkinson's Phase 1 Trial
NASDAQ · 10/07 11:37
Arvinas presents data from clinical trial of ARV-102
TipRanks · 10/07 11:05
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.